Metastatic hormone-sensitive prostate cancer: Practical guidelines and optimization of therapy selection
https://doi.org/10.17650/1726-9776-2018-14-4-139-149
Abstract
The treatment landscape for metastatic hormone-sensitive prostate cancer (mHSPC) has rapidly evolved over the past 5 years. Although androgen-deprivation therapy is still the backbone of treatment, the addition of docetaxel or abiraterone acetate has improved outcomes for patients with mHSPC and become standard of care. With multiple treatment options available for patients with mHSPC, treatment selection to optimize patient outcomes has become increasingly difficult. Here, we review the clinical trials involving androgen-deprivation therapy plus docetaxel or abiraterone and provide clinicians with guidelines for treatment. Although surgery and/or radiation are standard of care for localized, intermediate- and high-risk prostate cancer, these treatments are not routinely used as part of initial treatment plans for patients with de novo mHSPC. Recent clinical data are challenging that dogma, and we review the literature on the addition of surgery and radiation to systemic therapy for mHSPC.
About the Authors
R. A. Gafanov
Russian Scientific Center of Roentgen Radiology, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
86 Profsoyuznaya St., Moscow 117997.
Competing Interests:
The authors declare no conflict of interest.
A. G. Dzidzaria
Russian Scientific Center of Roentgen Radiology, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
86 Profsoyuznaya St., Moscow 117997.
Competing Interests:
The authors declare no conflict of interest.
I. B. Kravtsov
Russian Scientific Center of Roentgen Radiology, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
86 Profsoyuznaya St., Moscow 117997.
Competing Interests:
The authors declare no conflict of interest.
S. V. Fastovets
Russian Scientific Center of Roentgen Radiology, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
86 Profsoyuznaya St., Moscow 117997.
Competing Interests:
The authors declare no conflict of interest.
References
1. Malignant tumors in Russia in 2017 (morbidity and mortality). Eds.: A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena - filial FGBU “NMIRTS” Minzdrava Rossii, 2018. 250 p. (In Russ.).
2. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30. DOI: 10.3322/caac.21442. PMID: 29313949.
3. Jemal A., Fedewa S.A., Ma J. et al. Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA. 2015;314(19):2054—61. DOI: 10.1001/jama.2015.14905. PMID: 26575061.
4. Weiner A.B., Matulewicz R.S., Eggener S.E., Schaeffer E.M. Increasing incidence of metastatic prostate cancer in the United States (2004-2013). Prostate Cancer Prostatic Dis 2016;19(4):395—7. DOI: 10.1038/pcan.2016.30. PMID: 27431496.
5. Dalela D., Sun M., Diaz M. et al. Contemporary trends in the incidence of metastatic prostate cancer among US men: results from nationwide analyses. Eur Urol Focus 2017. DOI: 10.1016/j.euf.2017.04.012. PMID: 28753893.
6. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts. Prostate Cancer. Available at: https://seer.cancer.gov/statfacts/html/prost.html. Accessed January 7, 2018.
7. Huggins C., Hodges C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002;167(2 Pt 2):948-51, discussion 952. PMID: 11905923.
8. Sweeney C.J., Chen Y.H., Carducci M. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373(8): 737-46. DOI: 10.1056/NEJMoa1503747.
9. James N.D., Sydes M.R., Clarke N.W. et al. STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016;387(10024):1163—77. DOI: 10.1016/S0140-6736(15)01037-5. PMID: 26719232.
10. Gafanov R.A. Hormonal therapy and chemotherapy in patients with hormone-sensitive prostate cancer. Onkourologiya = Cancer Urology 2016;12(1):63-8. (In Russ.).
11. Fizazi K., Tran N., Fein L. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377(4):352—60. DOI: 10.1056/NEJMoa1704174. PMID: 28578607.
12. James N.D., de Bono J.S., Spears M.R. et al. STAMPEDE Investigators. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017;377:338-51.
13. Massie C.E., Lynch A., Ramos-Montoya A. et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J 2011;30(13):2719—33. DOI: 10.1038/emboj.2011.158. PMID: 21602788.
14. Harris W.P., Mostaghel E..A, Nelson P.S. et al. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009;6(2):76-85. DOI: 10.1038/ncpuro1296. PMID: 19198621.
15. Clinton T.N., Woldu S.L., Raj G.V. Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer. Expert Opin Pharmacother 2017;18(8):825—32. DOI: 10.1080/14656566.2017.1328056. PMID: 28480768.
16. Seidenfeld J., Samson D.J., Hasselblad V. et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000;132(7):566-77. PMID: 10744594.
17. Hussain M., Tangen C.M., Berry D.L. et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013;368(14):1314—25. DOI: 10.1056/NEJMoa1212299. PMID: 23550669.
18. Hussain M., Tangen C.M., Higano C. et al. Southwest Oncology Group Trial 9346 (INT-0162). Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006;24(24):3984-90. DOI: 10.1200/JCO.2006.06.4246. PMID: 16921051.
19. Klotz L., O’Callaghan C., Ding K. et al. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol 2015;33(10):1151-6. DOI: 10.1200/JCO.2014.58.2973. PMID: 25732157.
20. Hahn A.W., Hale P., Rathi N. et al. Novel androgen axis systemic therapies for metastatic hormone-sensitive prostate cancer. Curr Opin Urol 2017;27(6): 559-65. DOI: 10.1097/MOU.0000000000000443. PMID: 28816716.
21. McLeod D., Zinner N., Tomera K. et al. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 2001;58(5):756-61. PMID: 11711355.
22. Morote J., Esquena S., Abascal J.M. et al. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer. Urol Int 2006;77(2):135-8. DOI: 10.1159/000093907. PMID: 16888418.
23. Schulman C. Assessing the attitudes to prostate cancer treatment among European male patients. BJU Int 2007; 100 Suppl 1:6-11. DOI: 10.1111/j.1464-410X.2007.6976.x. PMID: 17593202.
24. Schulman C., Alcaraz A., Berges R. et al. Expert opinion on 6-monthly luteinizing hormone-releasing hormone agonist treatment with the single-sphere depot system for prostate cancer. BJU Int 2007;100 Suppl 1:1-5. DOI: 10.1111/j.1464-410X.2007.06967.x. PMID: 17593201.
25. Perez-Marrero R., Tyler R.C. A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer. Expert Opin Pharmacother 2004;5(2):447-57. DOI: 10.1517/14656566.5.2.447. PMID: 14996640.
26. Sartor O. Eligard: leuprolide acetate in a novel sustained-release delivery system. Urology 2003;61(2 Suppl 1):25— 31. PMID: 12667884.
27. Shore N.D., Chu F., Moul J. et al. Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer. BJU Int 2017;119(2):239—44. DOI: 10.1111/bju.13482. PMID: 26991743.
28. Sweeney C., Chen Y., Liu G. et al. Long term efficacy and QOL data of chemohormonal therapy in low and high volume hormone naive metastatic prostate cancer: E3805 CHAARTED trial. Ann Oncol 2016;27(suppl_6):243-65.
29. Gravis G., Fizazi K., Joly F. et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013;14(2):149—58. DOI: 10.1016/S1470-2045(12)70560-0. PMID: 23306100.
30. Gravis G., Boher J.M., Joly F. et al. GETUG. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU 15 Trial. Eur Urol 2016;70:256-62.
31. Sridhar S.S., Sweeney C.J. It is time to harmonize the design and conduct of clinical trials in metastatic hormone-sensitive prostate cancer. Eur Urol 2016;70(2):263—4. DOI: 10.1016/j.eururo.2015.11.025. PMID: 26683759.
32. Vale C.L., Burdett S., Rydzewska L.H.M. et al. STOpCaP Steering Group. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and metaanalyses of aggregate data. Lancet Oncol 2016;17:243-56.
33. de Bono J.S., Logothetis C.J., Molina A. et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21):1995—2005. DOI: 10.1056/NEJMoa1014618. PMID: 21612468.
34. Pavlov A.Yu., Gafanov RA, Tsybulskiy A.D. et al. Current strategy of drug therapy of metastatic and hormone-resistant prostate cancer. Rossiyskiy meditsinskiy zhurnal = Russian Medical Journal 2016;(8):476—9. (In Russ.).
35. Ryan C.J., Smith M.R., de Bono J.S. et al. COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368(2):138—48. DOI: 10.1056/NEJMoa1209096. PMID: 23228172.
36. Hoyle A. Role ofAAP + ADT in low- and high-risk mHNPC. ESMO 2018. Oral LBA4.
37. Scher H.I., Fizazi K., Saad F. et al. AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187—97. DOI: 10.1056/45.NEJMoa1207506. PMID: 22894553.
38. Beer T.M., Armstrong A.J., Rathkopf D.E. et al. PREVAIL Investigators. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371(18):424—33. DOI: 10.1056/NEJMc1410239. PMID: 25354111.46.
39. Alekseev B.Ya., Matveev V.B., Rusakov I.G. et al. Resolution on the results of the Meeting of Experts on the treatment of castrate-resistant prostate cancer. Onkourologiya = Cancer Urology 2016;12(3):109—10. (In Russ.).
40. Hussain M., Karim Fizazi K., Saad F. et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2018;378(26):2465—74. DOI: 10.1056/NEJMoa1800536. PMID: 29949494.
41. Small E.J., Saad F., Chowdhury S. et al. SPARTAN, a phase 3 doubleblind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC). J Clin Oncol 2018;36(6 suppl; abstr 161).
42. Rathkopf D.E., Antonarakis E.S., Shore N.D. et al. Safety and antitumor activity of apalutamide (ARN-509) in metastatic castration-resistant prostate cancer with and without prior abiraterone acetate and prednisone. Clin Cancer Res 2017;23(14):3544—51. DOI: 10.1158/1078-0432.CCR-16-2509. PMID: 28213364.
43. Shore N.D. Darolutamide (ODM-201) for the treatment of prostate cancer. Expert Opin Pharmacother 2017;18(9):945—52. DOI: 10.1080/14656566.2017.1329820. PMID: 28490267.
44. Fizazi K., Massard C., Bono P. et al. ARADES study group. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol 2014;15(9):975—85. DOI: 10.1016/S1470-2045(14)70240-2. PMID: 24974051.
45. Lenis A.T., Salmasi A.H., Donin N.M. et al. Trends in usage of cytoreductive partial nephrectomy and effect on overall survival in patients with metastatic renal cell carcinoma. Urol Oncol 2018;36(2): 78.e21—8. DOI: 10.1016/j.urolonc.2017.09.030. PMID: 29128421.
46. Culp S.H., Schellhammer P.F., Williams M.B. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol 2014;65(6):1058—66. DOI: 10.1016/j.eururo.2013.11.012. PMID: 24290503.
47. Tosoian J.J., Gorin M.A., Ross A.E. et al. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol 2017;14(1):15—25. DOI: 10.1038/nrurol.2016.175. PMID: 27725639.
48. Rusthoven C.G., Jones B.L., Flaig T.W. et al. Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer. J Clin Oncol 2016;34(24):2835—42. DOI: 10.1200/JCO.2016.67.4788. PMID: 27325855.
49. Satkunasivam R., Kim A.E., Desai M. et al. Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-Medicare analysis. J Urol 2015;194:378—85.
50. Gratzke C., Engel J., Stief C.G. Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry. Eur Urol 2014;66(3):602—3. DOI: 10.1016/j.eururo.2014.04.009. PMID: 24821581.
51. Cho Y., Chang J.S., Rha K.H. et al. Does radiotherapy for the primary tumor benefit prostate cancer patients with distant metastasis at initial diagnosis? PLoS One 2016;11(1):e0147191. DOI: 10.1371/journal.pone.0147191. PMID: 26807740.
52. Parker et al. Radiotherapy to the primary tumour for men with newly-diagnosed mPCa: survival results from STAMPEDE. ESMO 2018. Oral LBA5.
Review
For citations:
Gafanov R.A., Dzidzaria A.G., Kravtsov I.B., Fastovets S.V. Metastatic hormone-sensitive prostate cancer: Practical guidelines and optimization of therapy selection. Cancer Urology. 2018;14(4):139-149. (In Russ.) https://doi.org/10.17650/1726-9776-2018-14-4-139-149
Views:
3500
Email this article 